119 related articles for article (PubMed ID: 33355872)
21. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
23. CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Liu H; Peng F; Liu Z; Jiang F; Li L; Gao S; Wang G; Song J; Ruan E; Shao Z; Fu R
Int J Oncol; 2017 Feb; 50(2):631-639. PubMed ID: 28035364
[TBL] [Abstract][Full Text] [Related]
24. Increased Dickkopf-1 expression in breast cancer bone metastases.
Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.
Durie BG; Van Ness B; Ramos C; Stephens O; Haznadar M; Hoering A; Haessler J; Katz MS; Mundy GR; Kyle RA; Morgan GJ; Crowley J; Barlogie B; Shaughnessy J
Leukemia; 2009 Oct; 23(10):1913-9. PubMed ID: 19657367
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid hormone-related protein mRNA and protein expression in multiple myeloma: a case report.
Schneider HG; Kartsogiannis V; Zhou H; Chou ST; Martin TJ; Grill V
J Bone Miner Res; 1998 Oct; 13(10):1640-3. PubMed ID: 9783553
[TBL] [Abstract][Full Text] [Related]
27. SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.
Allegra A; Innao V; Polito F; Oteri R; Alibrandi A; Allegra AG; Oteri G; Di Giorgio RM; Musolino C; Aguennouz M
Clin Biochem; 2021 Jul; 93():42-49. PubMed ID: 33861984
[TBL] [Abstract][Full Text] [Related]
28. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell abnormalities in patients with multiple myeloma.
Garderet L; Mazurier C; Chapel A; Ernou I; Boutin L; Holy X; Gorin NC; Lopez M; Doucet C; Lataillade JJ
Leuk Lymphoma; 2007 Oct; 48(10):2032-41. PubMed ID: 17917971
[TBL] [Abstract][Full Text] [Related]
30. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.
Pellat-Deceunynck C; Barillé S; Jego G; Puthier D; Robillard N; Pineau D; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Leukemia; 1998 Dec; 12(12):1977-82. PubMed ID: 9844928
[TBL] [Abstract][Full Text] [Related]
31. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
[TBL] [Abstract][Full Text] [Related]
32. Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?
Chen P; Li B; Zhuang W; Huang H; Zhang H; Fu J
Int J Hematol; 2010 May; 91(4):716-22. PubMed ID: 20379806
[TBL] [Abstract][Full Text] [Related]
33. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.
Lazarevic V; Wahlin A; Hultdin M; Zhan F; Shaughnessy J
Leuk Lymphoma; 2006 Sep; 47(9):1987-8. PubMed ID: 17065022
[No Abstract] [Full Text] [Related]
35. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
36. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
[TBL] [Abstract][Full Text] [Related]
37. [Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
Bao L; Huang XJ
Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):243-7. PubMed ID: 21600091
[TBL] [Abstract][Full Text] [Related]
38. Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions.
Wang JH; Zhang Y; Li HY; Liu YY; Sun T
Medicine (Baltimore); 2016 Jun; 95(24):e3767. PubMed ID: 27310953
[TBL] [Abstract][Full Text] [Related]
39. Dickkopf-1 as a potential therapeutic target in Paget's disease of bone.
McCarthy HS; Marshall MJ
Expert Opin Ther Targets; 2010 Feb; 14(2):221-30. PubMed ID: 20055719
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of cell cycle proteins in multiple myeloma.
Pessach I; Papoudou-Bai A; Goussia A; Kamina S; Kyrtsonis MC; Bourantas KL; Kanavaros P
Leuk Lymphoma; 2015; 56(9):2720-3. PubMed ID: 25573203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
